Pulmonx (NASDAQ:LUNG) specializes in innovative medical technologies and solutions focused on improving the lives of people suffering from lung diseases, specifically those with severe emphysema. The company is renowned for its development, manufacture, and sale of minimally invasive medical devices aimed at enhancing pulmonary function and reducing the symptoms of lung conditions. Pulmonx's flagship product, the Zephyr Valve, is a revolutionary device that offers a nonsurgical treatment option for patients with emphysema, demonstrating the company's commitment to advancing respiratory health through innovation. With a strong emphasis on research and development, Pulmonx aims to continually expand its product portfolio, ensuring it meets the evolving needs of patients and healthcare professionals around the world.